The global diabetes epidemic continues to place enormous pressure on healthcare systems, and DPP-4 inhibitors like sitagliptin phosphate have become a widely prescribed oral therapy for managing type 2 diabetes. Valued for its favorable safety profile, low risk of hypoglycemia, and convenient once-daily dosing, sitagliptin phosphate remains a cornerstone treatment option, often used alone or in...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek